News Ascentage raises $126m in first biotech IPO of 2025 China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.
News AZ's Calquence gets first-line OK in mantle cell lymphoma AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.
News Grifols files drug for rare bleeding disorder in the US Grifols has filed for FDA approval of its new drug for bleeding disorder acquired fibrinogen deficiency (AFD), aiming for a first-in-class US launch.
News ASH: Blenrep ups survival by 42% in multiple myeloma trial GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.
News ASH: Regeneron plays its PNH hand Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.
News ASH: MSD’s ROR1 drug hits the target in first-line lymphoma The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.
